{
  "id": "5e44bdba48dab47f2600001c",
  "type": "yesno",
  "question": "Is Selumetinib effective for low-grade glioma?",
  "ideal_answer": "Selumetinib has promising antitumor activity in children with LGG.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31151904",
    "http://www.ncbi.nlm.nih.gov/pubmed/28339824"
  ],
  "snippets": [
    {
      "text": "Conclusion: Selumetinib has promising antitumor activity in children with LGG.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28339824",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\n\nSelumetinib is active in recurrent, refractory, or progressive pilocytic astrocytoma harbouring common BRAF aberrations and NF1-associated paediatric low-grade glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31151904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results show that selumetinib could be an alternative to standard chemotherapy for these subgroups of patients, and have directly led to the development of two Children's Oncology Group phase 3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low-grade glioma both with and without NF1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31151904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion Selumetinib has promising antitumor activity in children with LGG.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28339824",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION Selumetinib is active in recurrent, refractory, or progressive pilocytic astrocytoma harbouring common BRAF aberrations and NF1-associated paediatric low-grade glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31151904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Conclusion\n\nSelumetinib has promising antitumor activity in children with LGG.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28339824",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION\nSelumetinib is active in recurrent, refractory, or progressive pilocytic astrocytoma harbouring common BRAF aberrations and NF1-associated paediatric low-grade glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31151904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results show that selumetinib could be an alternative to standard chemotherapy for these subgroups of patients, and have directly led to the development of two Children's Oncology Group phase 3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low-grade glioma both with and without NF1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31151904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results show that selumetinib could be an alternative to standard chemotherapy for these subgroups of patients, and have directly led to the development of two Children's Oncology Group phase 3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low-grade glioma both with and without NF1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31151904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "INTERPRETATION: Selumetinib is active in recurrent, refractory, or progressive pilocytic astrocytoma harbouring common BRAF aberrations and NF1-associated paediatric low-grade glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31151904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Selumetinib is active in recurrent, refractory, or progressive pilocytic astrocytoma harbouring common BRAF aberrations and NF1-associated paediatric low-grade glioma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31151904",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These results show that selumetinib could be an alternative to standard chemotherapy for these subgroups of patients, and have directly led to the development of two Children's Oncology Group phase 3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low-grade glioma both with and without NF1.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31151904",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}